MedMira's HIV Test Approved Under USAID Initiative

Allows for International Purchase as Part of US Presidential Plan for AIDS Relief


MedMira Inc. announced that its Reveal G3 Rapid HIV-1 Antibody Test ("Reveal G3") has been approved for purchase by the U.S. Agency for International Development ("USAID"), resulting in the placement of Reveal G3 on USAID's rapid HIV test procurement list.

USAID's office of HIV/AIDS is responsible for leading the Agency's efforts within the President's Emergency Plan for AIDS Relief ("PEPFAR"); a $15 billion multifaceted approach to combating HIV and AIDS in over 100 countries, with particular emphasis on fifteen focus countries in Africa, Asia and Latin America. MedMira's inclusion on this procurement list enables Reveal G3 to be purchased for USAID-funded projects, and permits countries receiving USAID funding to purchase Reveal G3 under the PEPFAR program.

In order to be included on the USAID Procurement List, a rapid HIV test must meet certain performance specifications which, in turn, offers both the agency and the purchaser assurances that the product to be purchased is of the highest quality, safety and efficacy. Reveal G3 is the most advanced test in MedMira's Reveal product line, and was approved by the US Food and Drug Administration (FDA) only last year. Reveal G3 is one of only five products on the USAID list having FDA approval, thus offering purchasers of the test yet another level of confidence in product performance and quality.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances